Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
AssigneesBolder Biotechnology, Inc., Indiana University Research and Technology Corporation, The Medical College of Wisconsin, Inc.
InventorsGeorge N. Cox, Christie M. Orschell, Meetha Manek Medhora, Brian Fish
Life of this patent
Estimating the term…
Abstract
Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.
Claims12
A method of improving 30-day survival from hematopoietic acute radiation syndrome (H-ARS) in a subject who has been exposed to radiation comprising administering to the subject a combination therapy comprising an effective dose of an angiotensin-converting enzyme inhibitor (ACEI) and an effective dose of at least one hematopoietic growth factor (HGF) or protein analog thereof or combinations thereof;
- wherein the ACEI is selected from the group consisting of lisinopril, perindopril, captopril, enalapril, and ramipril;
- and
- wherein the HGF or protein analog thereof is selected from the group consisting of:
- peg-filgrastim;
- a G-CSF analog comprising a methionine at the N-terminus of SEQ ID NO:1, an IL-11 analog comprising a cysteine residue added following the C-terminus of the protein having SEQ ID NO:3 or SEQ ID NO;7, wherein the P1 amino acid is deleted;
- and
- wherein the survival obtained by treatment with the combination of at least one HGF or protein analog thereof and the ACEI is greater than the survival obtained by treatment with at least one HGF or protein analog thereof alone or treatment with the ACEI alone.
Dependencies are inferred from the claim text.